Codexis, Inc. (CDXS)
NASDAQ: CDXS · Real-Time Price · USD
2.820
+0.170 (6.42%)
At close: Apr 28, 2026, 4:00 PM EDT
2.818
-0.002 (-0.06%)
After-hours: Apr 28, 2026, 7:41 PM EDT
Company Description
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Codexis, Inc.
| Country | United States |
| Founded | 2002 |
| IPO Date | Apr 22, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 146 |
| CEO | Alison Moore |
Contact Details
Address: 200 Penobscot Drive Redwood City, California 94063 United States | |
| Phone | 650 421 8100 |
| Website | codexis.com |
Stock Details
| Ticker Symbol | CDXS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001200375 |
| CUSIP Number | 192005106 |
| ISIN Number | US1920051067 |
| Employer ID | 71-0872999 |
| SIC Code | 2860 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alison Moore Ph.D. | President, Chief Executive Officer and Director |
| Georgia L. Erbez | Chief Financial Officer and Chief Business Officer |
| Senator Byron L. Dorgan M.B.A. | Consultant |
| Dr. Stefan Lutz Ph.D. | Chief Scientific Officer |
| Carrie McKim | Director of Investor Relations |
| Britton Jimenez | Senior Vice President of Sales and Marketing |
| Karen Frechou-Armijo | Senior Vice President and Head of Human Resources |
| John Schiffhauer | Senior Vice President of Intellectual Property |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 14, 2026 | SCHEDULE 13G | Filing |
| Apr 14, 2026 | 8-K | Current Report |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 11, 2026 | 10-K | Annual Report |
| Mar 11, 2026 | 8-K | Current Report |
| Mar 11, 2026 | SCHEDULE 13G | Filing |
| Feb 23, 2026 | 144 | Filing |